Free Trial
NASDAQ:CORT

Corcept Therapeutics Q3 2025 Earnings Report

Corcept Therapeutics logo
$84.25 +1.14 (+1.37%)
Closing price 04:00 PM Eastern
Extended Trading
$84.85 +0.60 (+0.71%)
As of 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Corcept Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
$0.22
Beat/Miss
N/A
One Year Ago EPS
N/A

Corcept Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$223.78 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Corcept Therapeutics Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Wednesday, October 29, 2025
Conference Call Time
5:00PM ET

Conference Call Resources

Corcept Therapeutics Earnings Headlines

The $7 company helping Nvidia build the world’s first trillion-dollar robot …
Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.tc pixel
Corcept Therapeutics (NASDAQ:CORT) Rating Increased to Buy at Wall Street Zen
Corcept Primed For An Upside EPS Surprise
See More Corcept Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Corcept Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Corcept Therapeutics and other key companies, straight to your email.

About Corcept Therapeutics

Corcept Therapeutics (NASDAQ:CORT) is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery. Beyond Korlym, Corcept is advancing a proprietary pipeline of selective glucocorticoid receptor modulators, most notably relacorilant. Relacorilant is under investigation in multiple clinical trials for indications including endogenous Cushing’s syndrome, platinum-resistant ovarian cancer and psychotic major depression, reflecting Corcept’s commitment to expanding therapeutic options where cortisol dysregulation plays a key role.

Founded in 1998 and headquartered in Redwood City, California, Corcept went public in 2012 to support its transition from research to commercialization. Since then, the company has built a specialized commercial organization in the United States and is pursuing regulatory filings and partnerships in Europe and other regions. Corcept collaborates with academic institutions, clinical research centers and regulatory authorities to advance its programs from proof of concept through pivotal trials.

Corcept is led by President and CEO Joseph K. Belanoff, M.D., who co-founded the company and has guided its scientific and strategic direction for more than two decades. Under his leadership, Corcept has established a multidisciplinary team of researchers, clinicians and commercial experts. The company continues to explore novel approaches to glucocorticoid receptor modulation with the goal of delivering transformative therapies for patients affected by debilitating cortisol-related disorders.

View Corcept Therapeutics Profile

More Earnings Resources from MarketBeat